Eton Pharmaceuticals (ETON) appointed Judith Matthews as EVP, Accounting and Finance. Matthews will assume the role of CFO effective June 1. The company’s current CFO, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Gruber will remain in his role through May 31, and will subsequently enter into a six-month consulting agreement with Eton. Prior to joining Eton, she served as CFO of Iterum Therapeutics from 2015 to 2026. Previously, she was Vice President of Finance at Durata Therapeutics until its acquisition by Actavis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals Amends Credit Agreement, Eases Debt Terms
- Eton Pharmaceuticals Maps Aggressive Rare-Disease Growth Path
- Eton Pharmaceuticals price target raised to $52 from $37 at H.C. Wainwright
- Eton Pharmaceuticals: Expanding Rare-Disease Portfolio Underpins Attainable Growth Targets and Upside to $52 Price Target
- Eton Pharmaceuticals price target raised to $35 from $30 at Craig-Hallum